XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024

Das Instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

Das Instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

Das Instrument 5YL SE0005731833 BRAINCOOL AB EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument 5YL SE0005731833 BRAINCOOL AB EQUITY is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

Das Instrument 9L2 GB0007689002 KIN AND CARTA LS-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument 9L2 GB0007689002 KIN AND CARTA LS-,10 EQUITY is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

Das Instrument 49Y0 US05360L3042 AVENUE THERAP. DL-,0001 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument 49Y0 US05360L3042 AVENUE THERAP. DL-,0001 EQUITY is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

Das Instrument FB3S XS2472334403 LEVERAGE SHA ETP 2072 ETN wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument FB3S XS2472334403 LEVERAGE SHA ETP 2072 ETN is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

Das Instrument 3KWB XS2399370043 LEVERAGE SHA ETP 2071 ETN wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024
The instrument 3KWB XS2399370043 LEVERAGE SHA ETP 2071 ETN is traded cum capital adjustment on 25.04.2024 and ex capital adjustment on 26.04.2024

6 Richtige für 2025

Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!

Hier klicken

Zeit	Aktuelle Nachrichten
17.12.	Two partners with ABN AMRO to modernise B2B ecommerce payments
13.12.	"An Spielregeln der ABN-Amro-Gruppe halten": Das sagt Bethmann-Chef Hanegraaf über die Integration von HAL
11.12.	Felix Röhder wechselt zur ABN AMRO
09.12.	GFO-X Announces ABN AMRO Clearing, IMC, Standard Chartered Bank and Virtu Financial as Strategic Partners Ahead of Launch in Q1 2025	LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- GFO-X announces ABN AMRO Clearing, IMC, Standard Chartered Bank and Virtu Financial as strategic partners ahead of launch in Q1 2025. GFO-X is... ► Artikel lesen
03.12.	Christian Schmidt wird Leiter Transaction Banking der ABN Amro Deutschland

Zeit

Aktuelle Nachrichten

17.12.

Two partners with ABN AMRO to modernise B2B ecommerce payments

13.12.

"An Spielregeln der ABN-Amro-Gruppe halten": Das sagt Bethmann-Chef Hanegraaf über die Integration von HAL

11.12.

Felix Röhder wechselt zur ABN AMRO

09.12.

GFO-X Announces ABN AMRO Clearing, IMC, Standard Chartered Bank and Virtu Financial as Strategic Partners Ahead of Launch in Q1 2025

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- GFO-X announces ABN AMRO Clearing, IMC, Standard Chartered Bank and Virtu Financial as strategic partners ahead of launch in Q1 2025. GFO-X is...
► Artikel lesen

03.12.

Christian Schmidt wird Leiter Transaction Banking der ABN Amro Deutschland

Zeit	Aktuelle Nachrichten
27.11.	AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm	STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen
26.11.	AlzeCure Pharma to Present at Redeye Life Science Day on December 3	STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen
20.11.	AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm	STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen
11.11.	AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024	STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen
30.10.	AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD	STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen

Zeit

Aktuelle Nachrichten

27.11.

AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm

STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for...
► Artikel lesen

26.11.

AlzeCure Pharma to Present at Redeye Life Science Day on December 3

STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases...
► Artikel lesen

20.11.

AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm

STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases...
► Artikel lesen

11.11.

AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024

STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September...
► Artikel lesen

30.10.

AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD

STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting...
► Artikel lesen

Zeit	Aktuelle Nachrichten
29.11.	AVENUE THERAPEUTICS, INC. - 8-K, Current Report
15.11.	Avenue Therapeutics-Aktie erreicht 52-Wochen-Tief bei 1,68 US-Dollar
15.11.	Avenue Therapeutics GAAP EPS of -$1.92 misses by $0.92
14.11.	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of... ► Artikel lesen
15.10.	Avenue Therapeutics-Aktie erreicht 52-Wochen-Tief bei 1,89 US-Dollar

Zeit

Aktuelle Nachrichten

29.11.

AVENUE THERAPEUTICS, INC. - 8-K, Current Report

15.11.

Avenue Therapeutics-Aktie erreicht 52-Wochen-Tief bei 1,68 US-Dollar

15.11.

Avenue Therapeutics GAAP EPS of -$1.92 misses by $0.92

14.11.

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of...
► Artikel lesen

15.10.

Avenue Therapeutics-Aktie erreicht 52-Wochen-Tief bei 1,89 US-Dollar

Zeit	Aktuelle Nachrichten
01.11.	Braincool AB: BrainCool AB (publ) - Financial Report for Q3 2024	"149% Sales growth in segment BrainCool/IQool System in Q3 compared to same period last year" GroupThe period in briefQ32024Q32023Q1-Q32024Q1-Q32023Full year2023Net Sales8 8813 63827 92213 67223 227Total... ► Artikel lesen
15.08.	Braincool AB: BrainCool AB (publ) - Financial Report for Q2 2024	"42% Sales growth in Q2* and first patients in both COTTIS 2 and PRINCESS 2" GroupThe period in briefApr-Jun2024Apr-Jun2023Jan-Jun2024Jan-Jun2023Jan-Dec2023Net Sales10 4537 36619 04110 03423 227Total... ► Artikel lesen
25.04.	XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024	Das Instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024 The instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1... ► Artikel lesen

Zeit

Aktuelle Nachrichten

01.11.

Braincool AB: BrainCool AB (publ) - Financial Report for Q3 2024

"149% Sales growth in segment BrainCool/IQool System in Q3 compared to same period last year" GroupThe period in briefQ32024Q32023Q1-Q32024Q1-Q32023Full year2023Net Sales8 8813 63827 92213 67223 227Total...
► Artikel lesen

15.08.

Braincool AB: BrainCool AB (publ) - Financial Report for Q2 2024

"42% Sales growth in Q2* and first patients in both COTTIS 2 and PRINCESS 2" GroupThe period in briefApr-Jun2024Apr-Jun2023Jan-Jun2024Jan-Jun2023Jan-Dec2023Net Sales10 4537 36619 04110 03423 227Total...
► Artikel lesen

25.04.

XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024